A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Etanercept in the Treatment of Alcoholic Hepatitis
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Background Alcoholic hepatitis is a cause of major morbidity and mortality that lacks effective therapies. Both experimental and clinical evidence indicate that the multifunctional cytokine tumor necrosis factor-α (TNFα) contributes to pathogenesis and clinical sequelae of alcoholic hepatitis. A pilot study demonstrated that the TNFα-neutralizing molecule, etanercept, could be an effective treatment for patients with alcoholic hepatitis. Methods Forty-eight patients with moderate to severe alcoholic hepatitis (MELD score ≥15) were enrolled and randomized to groups that were given up to 6 subcutaneous injections of either etanercept or placebo for three weeks. Primary study endpoints included mortality at 1- and 6-month timepoints. Results There were no significant baseline differences between the placebo and etanercept groups in demographics or disease severity parameters including age, gender, and MELD score. The 1-month mortality rates of patients receiving placebo and etanercept were similar on an intention-to-treat basis (22.7% versus 36.4%, respectively; OR and 95% CI: 1.8 and 0.5–6.5). The 6-month mortality rate was significantly higher in the etanercept group, compared with the placebo group (57.7% versus 22.7%, respectively; OR and 95% CI: 4.6 and 1.3–16.4, p=0.017). Rates of infectious serious adverse events were significantly higher in the etanercept group, compared with the placebo group (34.6% versus 9.1%, p=0.04). Conclusion In patients with moderate to severe alcoholic hepatitis, etanercept was associated with a significantly higher mortality rate after 6 months, indicating that etanercept is not effective for the treatment of patients with alcoholic hepatitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Cytokines in Alcoholic and Nonalcoholic Steatohepatitis
Tilg, H., & Diehl, A. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432007 · Cited by 948
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
Akriviadis, E., Botla, R., Briggs, W., Han, S., Reynolds, T., & Shakil, O. (2000) · Gastroenterology · doi:10.1053/gast.2000.20189 · Cited by 800
Roach, D. R., Bean, A. G. D., Demangel, C., France, M. P., Briscoe, H., & Britton, W. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4620 · Cited by 782
Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α
Gorman, J. D., Sack, K. E., & Davis, J. C. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012664 · Cited by 704
Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice
Yin, M., Wheeler, M. D., Kono, H., Bradford, B. U., Gallucci, R. M., Luster, M. I., & Thurman, R. G. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70354-9 · Cited by 701
Leist, M., Gantner, F., Bohlinger, I., Tiegs, G., Germann, P., & Wendel, A. (1995) · Europe PMC (PubMed Central) · Cited by 537
MELD accurately predicts mortality in patients with alcoholic hepatitis†
Dunn, W., Jamil, L. H., Brown, L. S., Wiesner, R. H., Kim, W. R., Menon, K. V. N., Malinchoc, M., Kamath, P. S., & Shah, V. (2005) · Hepatology · doi:10.1002/hep.20503 · Cited by 530
Self-citationCarithers, R. L., Herlong, H. F., Diehl, A. M., Shaw, E. W., Combes, B., Fallon, H. J., & Maddrey, W. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-9-685 · Cited by 504
Cited by
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Gao, B., & Bataller, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.002 · Cited by 1,963
O'Shea, R. S., Dasarathy, S., & McCullough, A. J. (2010) · Hepatology · doi:10.1002/hep.23258 · Cited by 1,077
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
Thursz, M., Gual, A., Lackner, C., Mathurin, P., Moreno, C., Spahr, L., Sterneck, M., & Cortez-Pinto, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.018 · Cited by 943
Crabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L., & Lucey, M. R. (2020) · Hepatology · doi:10.1002/hep.30866 · Cited by 922
Lucey, M. R., Mathurin, P., & Morgan, T. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0805786 · Cited by 863
Alcoholic liver disease: mechanisms of injury and targeted treatment
Louvet, A., & Mathurin, P. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.35 · Cited by 855
ACG Clinical Guideline: Alcoholic Liver Disease
Singal, A. K., Bataller, R., Ahn, J., Kamath, P. S., & Shah, V. H. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.469 · Cited by 835
Self-citationAdverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759
EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.04.004 · Cited by 720
Acute-on chronic liver failure
Jalan, R., Gines, P., Olson, J. C., Mookerjee, R. P., Moreau, R., Garcia-Tsao, G., Arroyo, V., & Kamath, P. S. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.026 · Cited by 646
Self-citationPathogenesis of alcoholic liver disease: Role of oxidative metabolism
Ceni, E., Mello, T., & Galli, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i47.17756 · Cited by 521
Hepatocyte Death: A Clear and Present Danger
Malhi, H., Guicciardi, M. E., & Gores, G. J. (2010) · Physiological Reviews · doi:10.1152/physrev.00061.2009 · Cited by 477
Self-citationPierantonelli, I., & Svegliati-Baroni, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 460
Ki, S. H., Park, O., Zheng, M., Morales-Ibanez, O., Kolls, J. K., Bataller, R., & Gao, B. (2010) · Hepatology · doi:10.1002/hep.23837 · Cited by 434
Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure
Woolbright, B. L., & Jaeschke, H. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.11.017 · Cited by 390
Louvet, A., Wartel, F., Castel, H., Dharancy, S., Hollebecque, A., Canva–Delcambre, V., Deltenre, P., & Mathurin, P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.062 · Cited by 367
Alcohol-associated liver disease
Mackowiak, B., Fu, Y., Maccioni, L., & Gao, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176345 · Cited by 359
Hepatic inflammation and progressive liver fibrosis in chronic liver disease
Czaja, A. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2515 · Cited by 342
Tilg, H., Moschen, A. R., & Szabo, G. (2016) · Hepatology · doi:10.1002/hep.28456 · Cited by 319
Inflammation in Alcoholic Liver Disease
Wang, H. J., Gao, B., Zakhari, S., & Nagy, L. E. (2012) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-072610-145138 · Cited by 297
ACG Clinical Guideline: Alcohol-Associated Liver Disease
Jophlin, L. L., Singal, A. K., Bataller, R., Wong, R. J., Sauer, B. G., Terrault, N. A., & Shah, V. H. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002572 · Cited by 292
Self-citationRecent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease
Wu, X., Fan, X., Miyata, T., Kim, A., Cajigas-Du Ross, C. K., Ray, S., Huang, E., Taiwo, M., Arya, R., Wu, J., et al. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-030435 · Cited by 289
Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe?
Gao, B., & Tsukamoto, H. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.025 · Cited by 287
NLRP3 inflammasome driven liver injury and fibrosis: roles of IL-17 and TNF in mice
Wree, A., McGeough, M. D., Inzaugarat, M. E., Eguchi, A., Schuster, S., Johnson, C. D., Peña, C. A., Geisler, L. J., Papouchado, B. G., Hoffman, H. M., et al. (2018) · Hepatology · doi:10.1002/hep.29523 · Cited by 266
“However, caution must be taken because a randomized, placebo-controlled trial using etanercept was associated with a significantly higher mortality rate in patients with moderate-to-severe acute alcoholic hepatitis, an effect that was mainly attributed to an increased rate of severe infections.((49)) In summary, our c…”
Thabut, D., & Shah, V. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.004 · Cited by 266
Self-citationBataller, R., Arab, J. P., & Shah, V. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2207599 · Cited by 259
Self-citationApoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications
Alkhouri, N., Carter-Kent, C., & Feldstein, A. E. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.6 · Cited by 254
Dominguez, M., Miquel, R., Colmenero, J., Moreno, M., García–Pagán, J., Bosch, J., Arroyo, V., Ginès, P., Caballería, J., & Bataller, R. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.056 · Cited by 238
The Role of Intestinal Endotoxin in Liver Injury: A Long and Evolving History
Nolan, J. P. (2010) · Hepatology · doi:10.1002/hep.23917 · Cited by 229
“However, in contrast to the above studies was a randomized, double-blinded, placebo-controlled study of etanercept, in which the TNF-lowering receptor binding compound was used to lower TNFa in the treatment of alcoholic hepatitis.(42) Unfortunately, despite lowering of TNF levels, there was a significantly higher mor…”
ResultLiver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases
Ghabril, M., Bonkovsky, H. L., Kum, C., Davern, T., Hayashi, P. H., Kleiner, D. E., Serrano, J., Rochon, J., Fontana, R. J., & Bonacini, M. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.12.025 · Cited by 196
Alcoholic hepatitis: Translational approaches to develop targeted therapies
Mandrekar, P., Bataller, R., Tsukamoto, H., & Gao, B. (2016) · Hepatology · doi:10.1002/hep.28530 · Cited by 115
“Later studies in patients with AH using TNFa blocking agents and antioxidant cocktails were carried out with minimal positive outcomes.((32,48)) Thus, a more rational approach would be to perform integrative “omics” studies in human samples from patients with AH and use pathway/ network computational analysis to ident…”
BackgroundHyun, J., Sun, Z., Ahmadi, A. R., Bangru, S., Chembazhi, U. V., Du, K., Chen, T., Tsukamoto, H., Rusyn, I., Kalsotra, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci132691 · Cited by 76
Inflammation in Alcohol-Associated Hepatitis: Pathogenesis and Therapeutic Targets
Feng, D., Hwang, S., Guillot, A., Wang, Y., Guan, Y., Chen, C., Maccioni, L., & Gao, B. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.04.009 · Cited by 44
Pathogenesis of Alcohol-Associated Liver Disease
Mandrekar, P., & Mandal, A. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.06.005 · Cited by 34
Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease
Maccioni, L., Leclercq, I. A., Schnabl, B., & Stärkel, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312687 · Cited by 31
Metadata
- Authors
- Boetticher, N. C., Peine, C. J., Kwo, P., Abrams, G. A., Patel, T., Aqel, B., Boardman, L., Gores, G. J., Harmsen, W. S., McClain, C. J., Kamath, P. S., & Shah, V. H.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2008-12
- Volume
- 135
- Issue
- 6
- Pages
- 1953-1960
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2152084270
- Cited by
- 340
- References
- 42
- FWCI
- 14.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.